Barclays raised the firm’s price target on Neurocrine to $180 from $169 and keeps an Overweight rating on the shares post the Q2 report. The analyst says a “stellar Ingrezza print” nudges the stock’s base value floor higher. The firm remains positively biased into the ‘568 read-out and says the shares could reach $200 on positive data.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance
- NBIX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Neurocrine launches Ingrezza capsules for dysphagia
- Neurocrine price target raised to $170 from $160 at Morgan Stanley
- Neurocrine price target raised to $173 from $169 at JPMorgan